Table 2.

Effect of IM treatment on Bcr-Abl kinase activity and downstream signaling pathways in CD34⁺ cells expressing low and high levels of Bcr-Abl: percentage inhibition with IM treatment

IM, μM	MIG R1		BAlo		BAhi
	0.10	1.00	0.10	1.00	0.10	1.00
P-Bcr-Abl, n = 3*	NE	NE	68.7 ± 7.6	91.8 ± 6.8	55.2 ± 9.3	97.5 ± 6.1
P-Akt, n = 3†‡	−45.5 ± 41.7	−23.12 ± 32.1	12.5 ± 16	29.1 ± 28.9	44.5 ± 9.0	80.2 ± 4.7
P-MAPK, n = 3*	8.5 ± 28.3	−9.34 ± 4.7	69.6 ± 21.4	58 ± 28.5	66.2 ± 5.5	85.6 ± 2.8
P-STAT5, n = 4*	−28 ± 36	−32 ± 39	66.6 ± 13.1	73.5 ± 11.5	67.2 ± 5.4	94.2 ± 2.5
Bcl-XL, n = 3	−2.03 ± 10.72	−13.59 ± 23.66	23.98 ± 31.93	0.51 ± 43.17	36.38 ± 8.20	53.8 ± 4.6
Mcl-1, n = 2	−46.41 ± 67.25	−109.0 ± 103.9	61.05 ± 17.89	54.97 ± 7.9	71.82 ± 3.8	89.15 ± 4.77

Results are expressed as percentage relative to untreated control cells. Differences related to Bcr-Abl expression levels and IM exposure were analyzed using 2-way ANOVA; values are mean ± SEM.

^*P < .001[AU21] for IM-treated versus untreated cells.

^†P < .05 for IM-treated versus untreated cells.

^‡P = .01 for BA^lo versus BA^hi cells.